Software Review

Pharmaceuticals

Syndicate content Moreover Technologies
Moreover Technologies - Real-time news and blogs from thousands of sources
Updated: 3 weeks 6 days ago

BRIEF-Vectura signs licensing deal with GSK

Fri, 08/06/2010 - 1:54am
LONDON, Aug 6 (Reuters) - Vectura Group Plc: * And glaxosmithkline sign agreement to license some of vectura's dry powder drug formulation patents * Will receive up to £20 million in up-front and milestone payments * Will earn royalties capped at

Metabolism: Research from Astellas Pharma, Inc. has provided new information about metabolism

Fri, 08/06/2010 - 1:54am
Printer-Friendly Version City:Ibaraki Country:Japan Phosphatase New research, 'Glucose activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes,' is the subject of a report. "Lipid phosphatase SH2 domain-containing inositol

Transgene Biotek To Acquire US-based Marillion Pharma

Fri, 08/06/2010 - 1:53am
(RTTNews) - Transgene Biotek said on Thursday that it has signed a pact to buy Marillion Pharmaceuticals, a oncology bio-pharmaceuticals company based in Exton, Pennsylvania, through an all-share deal. Marillion Pharmaceuticals is a clinical-stage

Galapagos Initiates Phase I Study for JAK Inhibitor GLPG0634, Acquires Full Rights to Compound From GSK

Fri, 08/06/2010 - 1:43am
MECHELEN, BELGIUM--(Marketwire - 08/06/10) - Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with GSK.

UPDATE 1-Roche's Avastin gives best lung cancer survival rate

Fri, 08/06/2010 - 1:38am
ZURICH, Aug 6 (Reuters) - Roche's top-selling Avastin helps patients with the most common form of lung cancer live longer than any other treatment, the Swiss drugmaker said on Friday, giving the drug a boost after a slew of setbacks. A late-stage trial

Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rights to compound from GSK

Fri, 08/06/2010 - 1:36am
- Galapagos NV (Euronext: GLPG) announced todaythat it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, asmall molecule drug previously part of the Company arthritis alliance withGSK. Galapagos is initiating a Phase I clinical trial

Orica settles pharmaceuticals case with ATO

Fri, 08/06/2010 - 1:33am
Extract not available.

TABLE-Fuso Pharmaceutical <4538.T>-2010/11 group

Fri, 08/06/2010 - 1:31am
Aug 6 (Reuters) - FUSO PHARMACEUTICAL INDUSTRIES LTD CONSOLIDATED EARNINGS ESTIMATES (in billions of yen unless specified) Full year to Full year to March 31,2011 March 31,2011 LATEST PREVIOUS FORECAST FORECAST Sales 47.84 47.84 Operating 880 mln 880 mln

UPDATE 1-Roche's Avastin gives best lung cancer survival rate

Fri, 08/06/2010 - 1:31am
EDT * Avastin resulted in median overall survival of 14.2 months * Trial looked at Avastin with paclitaxel/carboplatin chemo (Adds details, background) ZURICH, Aug 6 (Reuters) - Roche's (ROG.VX) top-selling Avastin helps patients with the most common

Aska Pharmaceutical <4514.T>-1qtr group results

Fri, 08/06/2010 - 1:31am
3 months ended 3 months ended 6 months to Year to

Galapagos NV - Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rights to compound from GSK

Fri, 08/06/2010 - 1:20am
- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with GSK. Galapagos is initiating a Phase I clinical

Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rights to compound from GSK

Fri, 08/06/2010 - 1:16am
- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with GSK.� Galapagos is initiating a Phase I clinical

Galapagos Initiates Phase I Study for JAK Inhibitor GLPG0634, Acquires Full Rights to Compound From GSK

Fri, 08/06/2010 - 1:16am
MECHELEN, BELGIUM -- (Marketwire) -- 08/06/10 -- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with

Galapagos Initiates Phase I Study for JAK Inhibitor GLPG0634, Acquires Full Rights to Compound From GSK

Fri, 08/06/2010 - 1:12am
MECHELEN, BELGIUM -- (Marketwire) -- 08/06/10 -- Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with

Wanjia Pharma outsources production to Haohushi Pharma

Fri, 08/06/2010 - 1:11am
Extract not available.

Eighty-Three Percent of Surveyed Neurologists are Familiar with Emerging MS Agents Merck Serono/EMD

Fri, 08/06/2010 - 1:07am
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 83 percent of surveyed physicians are familiar with Merck Serono/EMD Serono's oral cladribine and Novartis/Mitsubishi Tanabe's

Re GSK Agreement

Fri, 08/06/2010 - 1:06am
Extract not available.

Galapagos Initiates Phase I Study for JAK Inhibitor GLPG0634, Acquires Full Rights to Compound From GSK

Fri, 08/06/2010 - 1:02am
Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline ( GSK | PowerRating GLPG0634 is an orally-available, novel candidate drug developed by Galapagos and selective against Janus kinase (JAK) 1 and 2 targets discovered

Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rights to compound from GSK

Fri, 08/06/2010 - 1:02am
SOURCE: Galapagos NV For full details on (GLPAY) GLPAY. (GLPAY) has Short Term PowerRatings at TradingMarkets. Details on (GLPAY) Short Term PowerRatings is available at This Link.

Galapagos Initiates Phase I Study for JAK Inhibitor GLPG0634, Acquires Full Rights to Compound From GSK

Fri, 08/06/2010 - 1:01am
Galapagos NV (Euronext: GLPG) announced today that it has acquired from GlaxoSmithKline ( GSK | PowerRating GLPG0634 is an orally-available, novel candidate drug developed by Galapagos and selective against Janus kinase (JAK) 1 and 2 targets discovered

Login

Username:

Password:

Poll

Which CI Software Vendor does your Organization Use?
Acuity
0%
Cipher
2%
Coemergence
9%
Comintell
15%
Digimind
3%
Novintel
18%
QL2
0%
Strategy
5%
Traction
0%
Wincite
7%
OTHER
10%
MULTIPLE
1%
NONE
31%
Total votes: 105

Online

1 guest and 0 users online: